Effect of organised mammography screening on stage-specific incidence in Norway: Population study

British Journal of Cancer

Volumn 114, Issue 5, 2016, Pages 590-596

  Lousdal, Mette L ^a   Kristiansen, Ivar S ^b   Møller, Bjørn ^c   Støvring, Henrik ^a  

^a AARHUS UNIVERSITY   (Denmark)

^b UNIVERSITY OF OSLO   (Norway)

^c CANCER REGISTRY OF NORWAY   (Norway)

Author keywords

breast cancer; cohort studies; lead time; mammography; screening; stage distribution

Indexed keywords

ADULT; ADVANCED CANCER; AGED; ARTICLE; BREAST CANCER; CANCER INCIDENCE; CANCER SCREENING; CANCER STAGING; CLINICAL CLASSIFICATION; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; HUMAN; ICD-10; INTRADUCTAL CARCINOMA; MAJOR CLINICAL STUDY; MAMMOGRAPHY; NORWAY; PERSONAL EXPERIENCE; POPULATION RESEARCH; PRIORITY JOURNAL; SCREENING TEST; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, INTRADUCTAL, NONINFILTRATING; DIAGNOSTIC IMAGING; EARLY CANCER DIAGNOSIS; INCIDENCE; MIDDLE AGED; PATHOLOGY; PROCEDURES;

ADULT; AGED; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, INTRADUCTAL, NONINFILTRATING; COHORT STUDIES; EARLY DETECTION OF CANCER; FEMALE; HUMANS; INCIDENCE; MAMMOGRAPHY; MIDDLE AGED; NORWAY;

EID: 84959420680     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2016.8     Document Type: Article

References (38)

1. Autier P. (2013). Mammography screening before introduction of the national breast screening programme in Norway. Int J Cancer. 132: 1721-1722.
2. Autier P, Boniol M. (2012). Breast cancer screening: evidence of benefit depends on the method used. BMC Med. 10: 163.
3. Autier P, Boniol M, Middleton R, Doré JF, Héry C, Zheng T, Gavin A. (2011). Advanced breast cancer incidence following population-based mammographic screening. Ann Oncol. 22: 1726-1735.
4. Biesheuvel C, Barratt A, Howard K, Houssami N, Irwig L. (2007). Effects of study methods and biases on estimates of invasive breast cancer overdetection with mammography screening: a systematic review. Lancet Oncol. 8: 1129-1138.
5. Black WC, Welch HG. (1993). Advances in diagnostic imaging and overestimations of disease prevalence and the benefits of therapy. N Engl J Med. 328: 1237-1243.
6. Bleyer A, Thomas CR, Baines C, Miller AB. (2015). Flawed assumptions used to defend screening mammography. Cancer. 121: 320-321.
7. Bleyer A, Welch HG. (2012). Effect of three decades of screening mammography on breast-cancer incidence. N Engl J Med. 367: 1998-2005.
8. Broeders M, Moss S, Nyström L, Njor S, Jonsson H, Paap E, Massat N, Duffy S, Lynge E, Paci E. (2012). The impact of mammographic screening on breast cancer mortality in Europe: a review of observational studies. J Med Screen. 19: 14-25.
9. de Glas NA, de Craen AJ, Bastiaannet E, Op 't Land EG, Kiderlen M, van de Water W, Siesling S, Portielje JE, Schuttevaer HM, de Bock GH, van de Velde CJ, Liefers GJ. (2014). Effect of implementation of the mass breast cancer screening programme in older women in the Netherlands: population based study. BMJ 349: g5410.
10. Erztaas AKO. (2003). Kvalitetsmanual: Mammografiprogrammet [Quality Manual: Organized Mammography]. The Cancer Registry of Norway: Oslo, Norway. Available from http://www.kreftregisteret.no/Global/.Kvalitetsmanualer/kvalitetsmanual-mammografiprogrammet.pdf
11. Esserman L, Shieh Y, Thompson I. (2009). Rethinking screening for breast cancer and prostate cancer. JAMA. 302: 1685-1692.
12. Falk RS. (2014). Why are results of organised mammography screening so difficult to interpret? Tidsskr Nor Legeforen. 134: 1124-1126.
13. Falk RS, Hofvind S, Skaane P, Haldorsen T. (2013). Overdiagnosis among women attending a population-based mammography screening program. Int J Cancer. 133: 705-712.
14. Feinstein AR, Sosin DM, Wells CK. (1985). The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer. N Engl J Med. 312: 1604-1608.
15. Giordano L, Karsa L, von, Tomatis M, Majek O, de Wolf C, Lancucki L, Hofvind S, Nystrom L, Segnan N, Ponti A. (2012). Mammographic screening programmes in Europe: organization, coverage and participation. J Med Screen. 19: 72-82.
16. Harris R, Yeatts J, Kinsinger L. (2011). Breast cancer screening for women ages 50 to 69 years a systematic review of observational evidence. Prev Med. 53: 108-114.
17. Helvie MA, Chang JT, Hendrick RE, Banerjee M. (2014). Reduction in latestage breast cancer incidence in the mammography era: implications for overdiagnosis of invasive cancer. Cancer. 120: 2649-2656.
18. Heuer C. (1997). Modeling of time trends and interactions in vital rates using restricted regression splines. Biometrics. 53: 161-177.
19. Hofvind S, Geller B, Vacek PM, Thoresen S, Skaane P. (2007). Using the European guidelines to evaluate the Norwegian Breast Cancer Screening Program. Eur J Epidemiol. 22: 447-455.
20. Hofvind S, Sakshaug S, Ursin G, Graff-Iversen S. (2012). Breast cancer incidence trends in Norway-explained by hormone therapy or mammographic screening? Int J Cancer. 130: 2930-2938.
21. Holli K, Isola J, Cuzick J. (1998). Low biologic aggressiveness in breast cancer in women using hormone replacement therapy. J Clin Oncol. 16: 3115-3120.
22. Irvin VL, Kaplan RM. (2014). Screening mammography &breast cancer mortality: meta-Analysis of quasi-experimental studies. PLoS One 9: e98105.
23. Kalager M, Zelen M, Langmark F, Adami HO. (2010). Effect of screening mammography on breast-cancer mortality in Norway. N Engl J Med. 363: 1203-1210.
24. Kopans DB. (2014). Study 'guesstimated' how many cancers would have occurred without mammography screening. BMJ 349: g6824.
25. Larsen IK, Småstuen M, Johannesen TB, Langmark F, Parkin DM, Bray F, Møller B. (2009). Data quality at the Cancer Registry of Norway: an overview of comparability, completeness, validity and timeliness. Eur J Cancer. 45: 1218-1231.
26. Lousdal ML, Kristiansen IS, Møller B, Støvring H. (2014). Trends in breast cancer stage distribution before, during and after introduction of a screening programme in Norway. Eur J Public Health. 24: 1017-1022.
27. Lynge E, Braaten T, Njor SH, Olsen AH, Kumle M, Waaseth M, Lund E. (2011). Mammography activity in Norway 1983 to 2008. Acta Oncol. 50: 1062-1067.
28. Manjer J, Malina J, Berglund G, Bondeson L, Garne JP, Janzon L. (2001). Increased incidence of small and well-differentiated breast tumours in post-menopausal women following hormone-replacement therapy. Int J Cancer. 92: 919-922.
29. Moons KG, Donders RA, Stijnen T, Harrell FE. (2006). Using the outcome for imputation of missing predictor values was preferred. J Clin Epidemiol. 59: 1092-1101.
30. Njor SH, Olsen AH, Blichert-Toft M, Schwartz W, Vejborg I, Lynge E. (2013). Overdiagnosis in screening mammography in Denmark: population based cohort study. BMJ 346: f1064.
31. Olsen AH, Njor SH, Lynge E. (2007). Estimating the benefits of mammography screening: the impact of study design. Epidemiology. 18: 487-492.
32. Sterne JA, White IR, Carlin JB, Spratt M, Royston P, Kenward MG, Wood AM, Carpenter JR. (2009). Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls. BMJ 338: b2393.
33. Sørum R, Hofvind S, Skaane P, Haldorsen T. (2010). Trends in incidence of ductal carcinoma in situ: the effect of a population-based screening programme. Breast. 19: 499-505.
34. Tabár L. (2014). Mammography screening study hampered by inadequate data. BMJ 349: g6823.
35. Vainio F, Bianchini F. (2002). IARC Handbook on Cancer Prevention. Vol. 7. Breast cancer screening. IARC Press: Lyon, France
36. Weedon-Fekjær H, Romundstad PR, Vatten LJ. (2014). Modern mammography screening and breast cancer mortality: population study. BMJ 348: g3701.
37. White IR, Royston P. (2009). Imputing missing covariate values for the Cox model. Stat Med. 28: 1982-1998.
38. White IR, Royston P, Wood AM. (2011). Multiple imputation using chained equations: Issues and guidance for practice. Stat Med. 30: 377-399.